INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 92 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2015. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $5,871,000 | +50.8% | 228,700 | -23.8% | 0.55% | +3.6% |
| Q2 2019 | $3,894,000 | +6.6% | 300,000 | 0.0% | 0.53% | +59.6% |
| Q1 2019 | $3,654,000 | +40.4% | 300,000 | +519.8% | 0.33% | -12.3% |
| Q4 2015 | $2,603,000 | -38.3% | 48,400 | -54.1% | 0.38% | -29.2% |
| Q3 2015 | $4,220,000 | +3.2% | 105,400 | -17.7% | 0.54% | +34.2% |
| Q2 2015 | $4,090,000 | +14.2% | 128,000 | -14.7% | 0.40% | +7.5% |
| Q1 2015 | $3,582,000 | +125.3% | 150,000 | +59.1% | 0.37% | -4.8% |
| Q2 2014 | $1,590,000 | -12.5% | 94,300 | -5.7% | 0.39% | -5.5% |
| Q1 2014 | $1,818,000 | – | 100,000 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |